Microcap Ledger Vanda Pharmaceuticals Inc. $VNDA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Washington, DC
- Fiscal year end
- December 31
- Shares outstanding
- 60,462,687 [10-Q 2026-08-06]
What the company doesAI summary of filing
Vanda Pharmaceuticals is a revenue-generating biopharmaceutical company that develops and commercializes prescription medications for psychiatric, neurological, sleep, and inflammatory disorders. The company's commercial portfolio includes four FDA-approved products: Fanapt for schizophrenia and bipolar I disorder, HETLIOZ for non-24-hour sleep-wake disorder and Smith-Magenis syndrome, PONVORY for relapsing multiple sclerosis, and NEREUS for motion sickness prevention. Vanda generates revenue from U.S. and international sales of these products and maintains an active pipeline of product candidates in clinical development, including additional indications for existing products and new molecular entities targeting psychiatric disorders, sleep disorders, inflammatory conditions, and rare diseases. [10-K 2026-02-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $102.25M | −$111.08M | −$81.29M | $55.88M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $216.10M | −$220.50M | −$109.44M | $84.85M | [10-K 2026-02-12] |
| FY ended Dec 2024 | $198.77M | −$18.90M | −$15.76M | $102.32M | [10-K 2026-02-12] |
- Quarterly cash burn
- −$40.64M
- Cash runway Estimate
- ~4.1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 58,308,144 | [10-Q 2024-11-07] |
| 2025-02-07 | 58,316,044 | [10-K 2025-02-14] |
| 2025-05-01 | 58,934,482 | [10-Q 2025-05-08] |
| 2025-07-24 | 59,089,130 | [10-Q 2025-07-31] |
| 2025-10-23 | 59,096,630 | [10-Q 2025-10-30] |
| 2026-02-05 | 59,108,030 | [10-K 2026-02-12] |
| 2026-04-30 | 60,135,562 | [10-Q 2026-05-07] |
| 2026-07-30 | 60,462,687 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-02-12; declared effective 2026-05-05 [S-3 2026-02-12]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-04 | Mcguire Daniel Patrick | grant | 80,000 | — | [4 2026-06-08] |
| 2026-06-04 | Chrousos Phaedra | grant | 41,600 | — | [4 2026-06-08] |
| 2026-06-04 | Duncan Charles Cliff | grant | 41,600 | — | [4 2026-06-08] |
| 2026-06-04 | Dugan Richard W | grant | 41,600 | — | [4 2026-06-08] |
| 2026-06-04 | Ward Anne Sempowski | grant | 41,600 | — | [4 2026-06-08] |
| 2026-06-04 | Honore Tage | grant | 41,600 | — | [4 2026-06-08] |
| 2026-06-04 | Mitchell Stephen Ray | grant | 41,600 | — | [4 2026-06-08] |
| 2026-05-18 | Mitchell Stephen Ray | other | 25,836 | — | [4 2026-05-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-19 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-06-05 | 8-K | Shareholder vote results |
| 2026-05-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-06 | 8-K | Results of operations |
| 2026-04-29 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-23 | DEF 14A | Proxy statement |
| 2026-04-22 | 8-K | Director or officer change |
Alerts for $VNDA
Email me when Vanda Pharmaceuticals Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.